Feasibility of consolidative immunotherapy and outcomes of chemoradiation for limited-stage small-cell lung cancer in the real world
Small-cell lung cancer (SCLC) is an aggressive disease presenting with limited stage (LS) in approximately 25% of cases. This study characterized the routine management of LS-SCLC as a benchmark for the advent of immune checkpoint inhibitors (ICI). A retrospective real-world cohort study of 533 consec...